Welcome to our dedicated page for Accelerate Diagnostics SEC filings (Ticker: AXDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Accelerate Diagnostics, Inc. (AXDX) provide detailed insight into its operations as an in vitro diagnostics company and document significant changes in its capital structure and corporate status. As described in its periodic reports and current reports on Form 8-K, the company develops diagnostic platforms focused on rapid microbial identification and phenotypic antimicrobial susceptibility testing to address antibiotic resistance and sepsis.
Annual reports on Form 10-K and quarterly reports on Form 10-Q, when available, contain audited and unaudited financial statements, managements discussion and analysis, and disclosures about research and development activities, commercialization of platforms such as the Accelerate Pheno system, Accelerate PhenoTest ae BC kit, and Accelerate Arc ae system, and the status of development programs like the Accelerate WAVE ae system. These filings also describe revenue composition, operating expenses, and liquidity considerations.
Current reports on Form 8-K are particularly important for Accelerate Diagnostics, as they capture material events including the voluntary Chapter 11 petitions filed on May 8, 2025 in the United States Bankruptcy Court for the District of Delaware, the entry into a stalking horse asset purchase agreement with an affiliate of Indaba Capital Management, L.P., court approval and consummation of the sale transaction, and confirmation of a Chapter 11 Plan of Liquidation. The August 18, 2025 Form 8-K also notes that the companys common stock was suspended from trading on The Nasdaq Capital Market and began trading on the OTC Pink marketplace under the symbol AXDXQ, and that all outstanding common stock and related equity interests will be canceled and discharged under the plan.
A Form 25 filed by The Nasdaq Stock Market LLC on July 21, 2025 documents the removal of Accelerate Diagnostics common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. A Form 12b-25 filed on August 18, 2025 explains delays in filing the Form 10-Q for the quarter ended June 30, 2025 due to the demands of the Chapter 11 cases and related sale transaction, and notes that the company expects significant changes in results of operations compared to the prior-year period.
On this filings page, users can review Forms 10-K and 10-Q for historical financial performance, Forms 8-K for material corporate events, and specialized filings such as Form 25 and Form 12b-25 that reflect listing status and reporting delays. Stock Titans interface can pair these documents with AI-generated highlights that summarize key points from lengthy reports, helping readers quickly understand issues such as revenue trends, research and development spending, liquidity risks, and the implications of the Chapter 11 Plan of Liquidation for common shareholders.
Accelerate Diagnostics, Inc. has notified regulators that it cannot file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 without unreasonable effort or expense. The company is operating under Chapter 11 bankruptcy in Delaware and has been pursuing an asset sale.
The court has approved a liquidation plan and an amended asset purchase agreement under which a buyer will acquire certain assets and liabilities. On the plan’s effective date, all outstanding common stock, related equity awards, and warrants will be canceled, and holders will not receive any property. The company notes its June 2025 results likely differ significantly from a year earlier due to these adverse developments and cannot estimate when or if it will file the 10-Q.
Accelerate Diagnostics, Inc. and its U.S. subsidiary filed voluntary Chapter 11 petitions and have entered an amended and restated Asset Purchase Agreement with an affiliate of Indaba Capital Management for the planned sale of company assets. The A&R Purchase Agreement narrows the buyer's acquisition to certain assets and liabilities rather than "substantially all" assets. The Bankruptcy Court entered a Confirmation Order approving the Second Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation, and the Company Parties intend to effect the transactions contemplated by the Plan after satisfaction or waiver of the Plan's conditions.
Nasdaq Stock Market LLC has filed Form 25 to remove Accelerate Diagnostics, Inc. (AXDX) common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The notice, signed on 2025-07-21 by Hearings Advisor Aravind Menon, states that Nasdaq believes it meets all requirements for the filing. The company’s securities will cease to be listed once the Form 25 becomes effective and the Exchange Act registration will be withdrawn unless the SEC objects. No financial or earnings data accompany this low-complexity filing; the sole purpose is the formal delisting of AXDX shares.
Gilbert E. Nathan has filed a Form 3 (Initial Statement of Beneficial Ownership) following his appointment as Director at Accelerate Diagnostics (AXDX). The filing, dated June 28, 2025, discloses Nathan's beneficial ownership position as of April 10, 2025.
Key details from the filing:
- Nathan currently holds no securities (derivative or non-derivative) beneficially owned in the company
- The filing confirms his position as Director but indicates no other roles such as Officer or 10% Owner
- This is an individual filing, not a joint/group submission
- Business address is listed as 3950 S. Country Club Road, Suite 470, Tucson, AZ 85714
This Form 3 filing is a standard regulatory requirement for new directors under Section 16(a) of the Securities Exchange Act of 1934, establishing a baseline for future ownership reporting.